The PI3K/AKT/mTOR pathway is one of the signaling cascades most commonly hijacked by cancer cells. Lymphoma cells are no exceptions. Thus, their pharmacological targeting is being extensively explored.
Following their previous work with the dual PI3K/mTOR inhibitor bimiralisib (PQR309) (PMID: 29066507), Dr Chiara Tarantelli and Prof. Francesco Bertoni from IOR, together with PD Anastasios Stathis from the local Oncology Institute of Southern Switzerland, and Dr Antonio Lupia, previous visiting fellow at IOR and currently at the University “Magna Græcia” of Catanzaro (Italy), have reviewed all the literature on the compounds belonging to this class. The extensive review, which covers both preclinical and clinical studies with a focus on the lymphoma setting, is now on-line in the International Journal of Molecular Sciences.
“Is There a Role for Dual PI3K/mTOR Inhibitors for Patients Affected with Lymphoma?”
By Chiara Tarantelli, Antonio Lupia, Anastasios Stathis and Francesco Bertoni
International Journal of Molecular Sciences 2020, 21(3), 1060; https://doi.org/10.3390/ijms21031060 (registering DOI)